Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Authors, Journal, Affiliations, Type, DOI
- Ania M. Jastreboff, Lee M. Kaplan, Melanie J. Davies, John P. H. Wilding, and co-authors for the TRIUMPH-1 Investigators; lead site Yale University School of Medicine.
- 131 sites in 11 countries.
- The New England Journal of Medicine, 2026;395:1781-1793 (November 5, 2026 issue); published online September 29, 2026, updated October 22, 2026.
- Type: phase 3, multicentre, randomized, double-blind, placebo-controlled trial with two embedded basket subpopulations.
- DOI: 10.1056/NEJMoa2604169. ClinicalTrials.gov: NCT05929066.
- Funded by Eli Lilly; the sponsor performed trial monitoring and data analysis.
Overview
TRIUMPH-1 randomized 2,339 adults with obesity and without diabetes to once-weekly retatrutide 4 mg, 9 mg or 12 mg or placebo for 80 weeks. With the treatment-regimen estimand, mean weight change was −17.6%, −23.7% and −25.0% versus −3.9% with placebo; with the efficacy estimand, up to −28.3%. In the 574 participants with knee osteoarthritis, WOMAC pain scores fell by 3.5–3.6 points at the 9- and 12-mg doses versus 1.9 with placebo, and in the 243 participants with obstructive sleep apnea the apnea–hypopnea index fell by 34.3 and 31.7 events per hour versus 9.9. The trial establishes retatrutide as the most potent obesity pharmacotherapy tested to date, at the cost of a dose-dependent gastrointestinal and neurological adverse-event profile.
Keywords
Retatrutide, triple hormone receptor agonist, GIP, GLP-1, glucagon, obesity, knee osteoarthritis, obstructive sleep apnea, cardiometabolic risk, randomized controlled trial
Key Takeaways
Background and Rationale
- Obesity affects more than 1 billion people worldwide and is heterogeneous in its pathophysiology.
- Mono-receptor agonists (liraglutide, semaglutide, orforglipron) and the dual GIP/GLP-1 agonist tirzepatide produce average weight reductions of 12–22% and improve obesity-related complications.
- Retatrutide adds glucagon receptor agonism to GIP and GLP-1 agonism; a phase 2 trial showed −24.2% weight at 48 weeks with 12 mg and improved waist circumference, blood pressure, glycated haemoglobin and lipids.
- TRIUMPH-1 was the phase 3 registrational test in obesity without diabetes, with embedded knee osteoarthritis and obstructive sleep apnea baskets.
Methods
- Adults ≥18 years with BMI ≥30, or BMI 27 to <30 with at least one obesity complication; enrolment enriched for BMI ≥35 (target 80%).
- Knee osteoarthritis basket: moderate or severe pain plus radiographic evidence. Obstructive sleep apnea basket: apnea–hypopnea index ≥15, with or without positive airway pressure therapy.
- Randomized 1:1:1:1 to retatrutide 4 mg, 9 mg or 12 mg or placebo, stratified by prediabetes status, sex and basket eligibility.
- All participants received physical-activity and healthy-diet counselling without purposeful caloric restriction; fixed dose-escalation schedule with up to two permanent dose reductions for gastrointestinal adverse events.
- Treatment 80 weeks, follow-up 4 weeks; the first approximately 500 participants entered a 24-week extension to week 104.
- Primary outcomes: percent change in body weight; change in WOMAC pain score in the knee osteoarthritis basket; change in apnea–hypopnea index in the obstructive sleep apnea basket — each for the 9-mg and 12-mg doses versus placebo.
- Weight-related endpoints used a treatment-regimen estimand (intention-to-treat); the osteoarthritis and sleep-apnea endpoints used a hybrid-treatment estimand with a hypothetical strategy for treatment-failure intercurrent events, with intention-to-treat results also reported.
Participants
- 2,339 randomized July 2023 to April 2026; 84.7% completed the trial (87.7–89.7% in retatrutide groups, 72.4% with placebo).
- Mean age 48.4 years; 65.6% women; mean body weight 112.7 kg; mean BMI 40.0; 77.4% had BMI ≥35.
- Knee osteoarthritis basket 574 participants (24.5%); obstructive sleep apnea basket 243 (10.4%); extension phase 532.
- At week 80, 74.5%, 58.7% and 54.0% of the 4-, 9- and 12-mg groups remained on their assigned dose.
Body Weight
- Treatment-regimen estimand, baseline to week 80: −17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg) versus −3.9% with placebo; differences −13.7, −19.8 and −21.0 percentage points (P<0.001 for all).
- Efficacy estimand: −19.0%, −25.9% and −28.3% versus +2.2% with placebo.
- Weight reduction ≥35%: 5.7–21.1% with retatrutide versus 0.2% with placebo.
- BMI <30 achieved in 40.1–57.1%; BMI <25 in 12.0–26.3%; waist-to-height ratio <0.5 in 10.1–20.4%.
- At week 104 (extension), treatment-regimen weight change was −18.9% with placebo switched to retatrutide, −25.7% with 4 mg, −28.7% with 9 mg and −29.9% with 12 mg; efficacy-estimand values were −19.2%, −27.9%, −29.5% and −30.3%.
- Weight reduction appeared greater in women than men at 12 mg (−26.3% versus −22.3%).
Knee Osteoarthritis
- Hybrid-treatment estimand, WOMAC pain change at week 80: −3.2 (4 mg), −3.5 (9 mg) and −3.6 (12 mg) versus −1.9 with placebo; differences for 9 and 12 mg −1.6 and −1.8 points (P<0.001).
- Intention-to-treat estimand: −3.4, −3.9 and −4.1 versus −2.5; differences −1.4 and −1.6 points (P<0.001).
Obstructive Sleep Apnea
- Hybrid-treatment estimand, apnea–hypopnea index change at week 80: −22.9, −34.3 and −31.7 events per hour versus −9.9; differences for 9 and 12 mg −24.4 and −21.9 (P<0.001).
- Intention-to-treat estimand: −22.8, −34.3 and −32.1 versus −9.6; differences −24.7 and −22.5 (P<0.001).
Cardiometabolic and Patient-Reported Outcomes
- Waist circumference change −15.7, −20.1 and −21.6 cm; systolic blood pressure −7.6, −9.8 and −10.4 mmHg.
- Triglycerides −30.9%, −36.4% and −38.0%; non-HDL cholesterol −16.7%, −21.9% and −20.6%; fasting insulin −43.1%, −51.9% and −54.5%; high-sensitivity C-reactive protein −57.7%, −61.6% and −62.6%.
- Among participants with prediabetes at baseline, reversion to normoglycaemia occurred in 89.4–93.2% with retatrutide versus 54.2% with placebo.
- SF-36v2 physical-function and IWQOL-Lite-CT physical and psychosocial scores improved more with retatrutide than placebo (P<0.001).
Safety
- At least one adverse event: 87.0–89.2% with retatrutide versus 80.7% with placebo; most commonly nausea, diarrhoea and constipation, mostly transient and mild or moderate during dose escalation.
- Treatment discontinuation for adverse events: 4.1%, 6.5% and 11.1% versus 4.6%; discontinuation for perceived excessive weight loss: 0.3%, 1.0% and 5.3% versus 0%.
- Permanent dose reduction: 7.5%, 18.4% and 22.5% versus 0.5%.
- Serious adverse events: 7.7%, 7.7% and 10.5% versus 5.5%.
- Deaths: 0, 3 (0.5%) and 1 (0.2%) versus 2 (0.3%); adjudicated major adverse cardiovascular events: 1, 5 and 3 participants versus 1.
- Adverse events of special interest more frequent with retatrutide: dysesthesia (5.1%, 12.3%, 12.5% versus 0.9%), injection-site reactions (5.5%, 8.9%, 12.2% versus 3.8%) and hypotension (2.7%, 5.3%, 8.8% versus 0.9%).
- Pulse rate increased, peaking at week 20 at the 9- and 12-mg doses and declining thereafter.
- No medullary thyroid cancer or drug-induced liver injury; urinary tract infections 7.5–8.7% versus 5.3%, 92% in women.
- Adjudication-confirmed pancreatitis occurred in 1, 3 and 4 participants versus 2; the numbers are too small for conclusions.
Interpretation
- Retatrutide produced weight loss approaching that of bariatric surgery, with more than one third of participants losing at least 30% of body weight and about one fifth losing at least 35%.
- The results support a treat-to-target approach to obesity — for example, targeting a BMI threshold or a defined percentage weight reduction — rather than a maximum-tolerated-dose strategy.
- The trial was not powered for cardiovascular safety; TRIUMPH-Outcomes (NCT06383390) is evaluating cardiovascular and kidney outcomes.
Limitations of the Document
- No active comparator; greater attrition in the placebo group may have been influenced by access to other obesity medications.
- Only 2% of participants had a baseline BMI <30, limiting generalizability to milder obesity.
- The trial was not powered to assess cardiovascular safety or mortality.
- The knee osteoarthritis and obstructive sleep apnea baskets were subpopulations of the main obesity trial, not independently powered registrational trials.
- The extension phase was limited to approximately 500 participants and 24 weeks.
- The sponsor performed trial monitoring and data analysis, although all authors had access to the data.
Key Concepts Mentioned
- concepts/GLP-1-Receptor-Agonists — the incretin class and its cardiovascular evidence
- concepts/NuSH-Therapies — nutrient-stimulated hormone therapies for obesity
- concepts/HFpEF-Management — obesity-HFpEF as a downstream phenotype
- concepts/Obesity-Paradox — intentional versus unintentional weight loss
- concepts/Visceral-Adiposity — the mechanistic target of incretin-based therapy
Key Entities Mentioned
- entities/Retatrutide — the drug, its pharmacology and the TRIUMPH programme
- entities/Tirzepatide — the dual GIP/GLP-1 comparator
- entities/Semaglutide — the GLP-1 comparator
- entities/Obesity — the treated disease
- entities/Obstructive-Sleep-Apnea — one of the two basket populations
- entities/MASLD — the liver phenotype of obesity
Wiki Pages Updated
wiki/sources/Retatrutide-Obesity-NEJM-2026.md— created (this file)wiki/entities/Retatrutide.md— createdwiki/concepts/GLP-1-Receptor-Agonists.md— updated with the triple-agonist evidencewiki/concepts/NuSH-Therapies.md— updated with retatrutidewiki/concepts/HFpEF-Management.md— updated with the class contextwiki/entities/Tirzepatide.md— updated with the retatrutide comparisonwiki/entities/Obesity.md— updated with the TRIUMPH-1 resultwiki/wikiindex.md— updatedwiki/sourceindex.md— updated